|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
D'Antonio C, Passaro A, Gori B, Del
Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F:
Bone and brain metastasis in lung cancer: Recent advances in
therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang PQ, Wu YX, Zhong XD, Liu B and Qiao
G: Prognostic significance of overexpressed long non-coding RNA
TUG1 in patients with clear cell renal cell carcinoma. Eur Rev Med
Pharmacol Sci. 21:82–86. 2017.PubMed/NCBI
|
|
5
|
Wang Y, Zhang W, Wang Y and Wang S:
HOXD-AS1 promotes cell proliferation, migration and invasion
through miR-608/FZD4 axis in ovarian cancer. Am J Cancer Res.
8:170–182. 2018.PubMed/NCBI
|
|
6
|
Ricciuti B, Mencaroni C, Paglialunga L,
Paciullo F, Crino L, Chiari R and Metro G: Long noncoding RNAs: New
insights into non-small cell lung cancer biology, diagnosis and
therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y and Tang L: The application of
lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer
Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L, Dzakah EE and Shan G: Targetable
long non-coding RNAs in cancer treatments. Cancer Lett.
418:119–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atmadibrata B, Liu PY, Sokolowski N, Zhang
L, Wong M, Tee AE, Marshall GM and Liu T: The novel long noncoding
RNA linc00467 promotes cell survival but is down·regulated by
N-Myc. Plos One. 9:e881122014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh H, Li Y, Fuller PJ, Harrison C, Rao
J, Stephens AN and Nie G: HtrA3 is downregulated in cancer cell
lines and significantly reduced in primary serous and granulosa
cell ovarian tumors. J Cancer. 4:152–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Gong L, Qi R, Sun Q, Xia X, He H,
Ren J, Zhu O and Zhou D: Paeoniflorin suppresses pancreatic cancer
cell growth by upregulating HTRA3 expression. Drug Des Devel Ther.
11:2481–2491. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin Y, Wu M, Nie G, Wang K, Wei J, Zhao M
and Chen Q: HtrA3 is negatively correlated with lymph node
metastasis in invasive ductal breast cancer. Tumour Biol.
34:3611–3617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim D, Langmead B and Salzberg SL: HISAT:
A fast spliced aligner with low memory requirements. Nat Methods.
12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pertea M, Pertea GM, Antonescu CM, Chang
TC, Mendell JT and Salzberg SL: StringTie enables improved
reconstruction of a transcriptome from RNA-seq reads. Nat
Biotechnol. 33:290–295. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pertea M, Kim D, Pertea GM, Leek JT and
Salzberg SL: Transcript-level expression analysis of RNA-seq
experiments with HISAT, StringTie and Ballgown. Nat Protoc.
11:1650–1667. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society:
International multidisciplinary classification of lung
adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malek E, Jagannathan S and Driscoll JJ:
Correlation of long non-coding RNA expression with metastasis, drug
resistance and clinical outcome in cancer. Oncotarget. 5:8027–8038.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Wang R, Zhang K and Chen LB: Long
non-coding RNAs in non-small cell lung cancer as biomarkers and
therapeutic targets. J Cell Mol Med. 18:2425–2436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia H, Jing H, Li Y and Lv X: Long
noncoding RNA HOXD-AS1 promotes non-small cell lung cancer
migration and invasion through regulating miR-133b/MMP9 axis.
Biomed Pharmacother. 106:156–162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Gesualdo F, Capaccioli S and Lulli M: A
pathophysiological view of the long non-coding RNA world.
Oncotarget. 5:10976–10996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang L, Ge D, Chen X, Qiu J, Yin Z, Zheng
S and Jiang C: FOXP4-AS1 participates in the development and
progression of osteosarcoma by downregulating LATS1 via binding to
LSD1 and EZH2. Biochem Biophys Res Commun. 502:493–500. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu
TC, Tang JY, Bao YJ, Hu Y, Lin Y, et al: A novel lncRNA GClnc1
promotes gastric carcinogenesis and may act as a modular scaffold
of WDR5 and KAT2A complexes to specify the histone modification
pattern. Cancer Discov. 6:784–801. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takashina T, Kinoshita I, Kikuchi J,
Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M and
Dosaka-Akita H: Combined inhibition of EZH2 and histone
deacetylases as a potential epigenetic therapy for non-small-cell
lung cancer cells. Cancer Sci. 107:955–962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Chen D, Shen W, Chen L, Yu A, Fu H,
Sun K and Sun X: EZH2 mediates the regulation of S100A4 on
E-cadherin expression and the proliferation, migration of gastric
cancer cells. Hepatogastroenterology. 62:737–741. 2015.PubMed/NCBI
|
|
29
|
McDevitt MA: Clinical applications of
epigenetic markers and epigenetic profiling in myeloid
malignancies. Semin Oncol. 39:109–122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Leenders GJ, Dukers D, Hessels D, van
den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ and
Raaphorst FM: Polycomb-group oncogenes EZH2,BMIl and RINGl are
overexpressed in prostate cancer with adverse pathologic and
clinical features. Eur Urol. 52:455–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoo KH and Hennighausen L: EZH2
methyltransferase and H3K27 methylation in breast cancer. Int J
Biol Sci. 8:59–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Benard A, Goossens-Beumer IJ, van Hoesel
AQ, Horati H, Putter H, Zeestraten EC, van de Velde CJ and Kuppen
PJ: Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and
histone modification H3K27me3 in colorectal cancer. PLoS One.
9:e1082652014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gannon OM, Merida de Long L, Endo-Munoz L,
Hazar-Rethinam M and Saunders NA: Dysregulation of the repressive
H3K27 trimethylation mark in head and neck squamous cell carcinoma
contributes to dysregulated squamous differentiation. Clin Cancer
Res. 19:428–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saito M, Saito K, Shiraishi K, Maeda D,
Suzuki H, Minamiya Y, Kono K, Kohno T and Goto A: Identification of
candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T
therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol
Clin Oncol. 8:310–314. 2018.PubMed/NCBI
|
|
35
|
Clausen T, Southan C and Ehrmann M: The
HtrA family of proteases: Implications for protein composition and
cell fate. Mol Cell. 10:443–455. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao J, Zhang J, Zhang X, Feng M and Qu J:
High temperature requirement A3 (HTRA3) expression predicts
postoperative recurrence and survival in patients with
non-small-cell lung cancer. Oncotarget. 7:40725–40734.
2016.PubMed/NCBI
|
|
37
|
Wenta T, Zurawa-Janicka D, Rychlowski M,
Jarzab M, Glaza P, Lipinska A, Bienkowska-Szewczyk K,
Herman-Antosiewicz A, Skorko-Glonek J and Lipinska B: HtrA3 is a
cellular partner of cytoskeleton proteins and TCP1α chaperonin. J
Proteomics. 177:88–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
